This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dzierszinski, F.
Right arrow Articles by Tomavo, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dzierszinski, F.
Right arrow Articles by Tomavo, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2002, p. 3197-3207, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3197-3207.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Ligands of the Peripheral Benzodiazepine Receptor Are Potent Inhibitors of Plasmodium falciparum and Toxoplasma gondii In Vitro

Florence Dzierszinski,1,{dagger} Alexandra Coppin,1 Marlene Mortuaire,1 Etienne Dewailly,2 Christian Slomianny,2 Jean-Claude Ameisen,3 Frederic DeBels,3 and Stanislas Tomavo1*

Equipe de Parasitologie Moléculaire, Laboratoire de Chimie Biologique, CNRS UMR 8576,1 Laboratoire de Physiologie Cellulaire, INSERM EPI-9938, Université des Sciences et Technologies de Lille, 59655 Villeneuve d'Ascq,2 EMI-9922 INSERM-Université Paris 7, Groupe Hospitalier Bichat-Claude Bernard, 75877 Paris, France3

Received 27 December 2001/ Returned for modification 12 March 2002/ Accepted 2 July 2002

The increase in resistance of the malaria parasite Plasmodium falciparum to currently available drugs demands the development of new antimalarial agents. In this quest, we have found that ligands to the peripheral benzodiazepine receptor such as flurazepam, an agonist of the benzodiazepine family, and PK11195, an antagonist derived from isoquinoline, were active against Plasmodium falciparum. These two compounds effectively and rapidly inhibited parasite growth in vitro, irrespective of parasite resistance to chloroquine and mefloquine. Treatment with both drugs induced a sharp and consistent decline in parasitemia, a complete inhibition of parasite replication, and the destruction of parasites within the host red blood cells. Using electron microscopy, we showed that dramatic morphological changes, involving swollen endoplasmic reticulum and the reduction of hemozoin, were consistent with parasite death. The potent activities of flurazepam and PK11195 were also evaluated for antagonist or synergistic effects with currently used antimalarial drugs such as chloroquine and mefloquine. Moreover, flurazepam was found to be active against Toxoplasma gondii, another member of the phylum Apicomplexa. Taken together, our results indicated that benzodiazepines could be considered promising candidates in the treatment of both malaria and toxoplasmosis.

* Corresponding author. Mailing address: Equipe de Parasitologie Moléculaire, Laboratoire de Chimie Biologique, CNRS UMR 8576, BÂtiment C9, Université des Sciences et Technologies de Lille, 59655 Villeneuve d'Ascq, France. Phone: 33 3 20 43 69 41. Fax: 33 3 20 43 65 55. E-mail: Stan.Tomavo{at}univ-lille1.fr.

{dagger} Present address: Department of Biology, University of Pennsylvania, Philadelphia, PA 19104-6018.

Antimicrobial Agents and Chemotherapy, October 2002, p. 3197-3207, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3197-3207.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»